Is Revolution Medicines Inc (RVMD) Stock About to Get Hot Friday?

Revolution Medicines Inc (RVMD) stock is higher by 27.08% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

Revolution Medicines Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on RVMD!

See Full RVMD Report

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With RVMD Stock Today?

Revolution Medicines Inc (RVMD) stock is trading at $23.65 as of 12:40 PM on Friday, Nov 3, a rise of $2.50, or 11.82% from the previous closing price of $21.15. The stock has traded between $21.23 and $23.81 so far today. Volume today is below average. So far 960,470 shares have traded compared to average volume of 3,655,510 shares.

More About Revolution Medicines Inc

Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products include RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs. Click Here to get the full Stock Report for Revolution Medicines Inc stock.